Chemotherapy for Prostate Cancer

Author(s): Sara W. Dyrstad, Prabodh Shah, K. Rao

Journal Name: Current Pharmaceutical Design

Volume 12 , Issue 7 , 2006

Become EABM
Become Reviewer


Androgen deprivation in patients with metastatic prostate cancer produces palliation of symptoms, reduction in PSA levels, and temporary regression of tumor in most patients. Following a brief period of disease regression that lasts an average of eighteen to twenty-four months, the disease becomes hormone refractory and progresses. Second line hormonal manipulation includes anti-androgen withdrawal, glucocorticoids, estrogens, aminogluthetimide, and ketoconazole. The response from these drugs is usually very short. Once these measures have been exhausted, the clinician is left with limited treatment options that include radionuclides and cytotoxic chemotherapy. It is the objective of this article to review the experience with chemotherapy in prostate cancer and then to discuss the role of radionuclide agents, emerging agents, and herbal therapies.

Keywords: Radioisotopes, bone metastases, taxanes, Mitoxantrone, prostate specific antigen (PSA), prednisone, Small cell carcinoma

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [819 - 837]
Pages: 19
DOI: 10.2174/138161206776056100
Price: $65

Article Metrics

PDF: 1